These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 5069316)
101. [Advantages and limitations of the galactosamine model]. Decker K Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():245-9. PubMed ID: 1029184 [No Abstract] [Full Text] [Related]
102. [The effect of D-penicillamine on the galactosamine hepatitis model in the rat]. Habersang S; Kozlik V; Leuschner F; von Schlichtegroll A Arzneimittelforschung; 1973 Jan; 23(1):56-7. PubMed ID: 4740696 [No Abstract] [Full Text] [Related]
103. Effect of partial hepatectomy on the hepatotoxicity of D-galactosamine. Andreicuţ S; Kerekes M Morphol Embryol (Bucur); 1982; 28(2):177-84. PubMed ID: 6213854 [No Abstract] [Full Text] [Related]
104. ["Galactosamine refractory" regenerating liver--a model for studies on the etiology mechanism of galactosamine hepatitis]. Reutter W; Bauer C; Bachmann W; Lesch R Hoppe Seylers Z Physiol Chem; 1972 May; 353(5):747. PubMed ID: 5069316 [No Abstract] [Full Text] [Related]
106. Mechanism and clinical relevance of elevated levels of circulating asialoglycoproteins. Sawamura T; Shiozaki Y Targeted Diagn Ther; 1991; 4():215-34. PubMed ID: 1797157 [No Abstract] [Full Text] [Related]
107. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Decker K; Keppler D Rev Physiol Biochem Pharmacol; 1974; (71):77-106. PubMed ID: 4375846 [No Abstract] [Full Text] [Related]